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The influence of Castanea sativa Mill. flower
extract on hormonally and chemically induced
prostate cancer in a rat model
E. Nascimento-Gonçalves,a,b F. Seixas,†c M. Silva,†d M. Fardilha,e R. Ferreira,b
M. J. Neuparth,f A. I. Faustino-Rocha,a,g B. Colaço,a C. Venâncio,a L. Barros, h
I. C. F. R. Ferreira, h M. M. Oliveira, d F. Peixoto,d E. Rosaa and P. A. Oliveira *a
Prostate cancer (PCa) is one of the most common cancers in men, with a huge impact on their health.
The use of Castanea sativa Mill. flowers (CFs) in beverages has been reported, through ancestral claims, as
having health benefits. In vitro research has evidenced the properties of CFs, such as antitumor and anti-
oxidant activities. This study aimed to evaluate the effects of CF extract in an animal model of PCa. Forty
male Wistar Unilever rats were randomly assigned to four groups: control, induced, control + CF, and
induced + CF groups. Animals from the induced groups were exposed to a multistep protocol for PCa
induction. The CF extract, rich in trigalloyl-HHDP-glucoside and obtained via decoction, was administered
to the CF groups in drinking water (3 mg per animal per day) for 49 weeks. Animals were sacrificed at 61
weeks of age. Regarding the effects of CFs on dorsolateral prostate tumorigenesis, no significant differ-
ences were observed between the induced and induced + CF groups. However, animals exposed to the
CF extract showed fewer inflammation areas on the dorsolateral prostate lobe than those not exposed to
CF. Moreover, the CF extract alleviated the hepatic oxidative stress associated with the multistep protocol,
resulting in lower levels of lipid peroxidation. These results suggest that CF extract has antioxidant and
anti-inflammatory properties.
1. Introduction
Prostate cancer (PCa) is the second most common cancer in
men, affecting approximately 1.3 million men worldwide.1
Many risk factors have been associated with PCa development
namely age, race, family history, diet, hormone exposure and
inflammation.2,3 Chemoprevention plays an important role in
cancer prevention and progression (conversion of tumor cells
to a malignant phenotype and to invasive disease).4 Natural
compounds have been widely used to prevent and even treat
several diseases, including cancer.5,6 Over 60% of anti-cancer
drugs are obtained from natural products, including plants,
marine organisms and microbes.5 The active ingredients from
natural products, such as alkaloids, flavonoids, terpenoids,
polysaccharides and saponin, have different anti-cancer activi-
ties. These compounds may inhibit cell proliferation, induce
apoptosis, and reduce the activity of metalloproteinases and
cell invasion.7 Additionally, natural compounds also exhibit
anti-inflammatory, analgesic, immunomodulatory and anti-
viral properties.5 Until now, several natural compounds were
experimentally evaluated in in vivo PCa models. For example,
the incidence of invasive carcinomas in Lobund-Wistar rats
induced by N-methyl-N-nitrosourea (MNU) and treated with
genistein, an isoflavone of soy, was lower when compared with
non-treated animals.8 Acticoa powder, a cocoa polyphenolic
extract, reduced the incidence of PCa in Wistar-Unilever rats
exposed to MNU, followed by chronic androgen stimulation
with testosterone.9 Crataeva nurvala, a typical Indian medicinal
plant, showed anticancer activity against MNU-induced PCa in
Wistar rats.10 These results support the use of this PCa model†Both authors contributed in the same way to this work.
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to evaluate chemopreventive and therapeutic properties of
natural compounds.
Chestnuts are trees with a high impact on the Portuguese
economy, mainly in the north-east of the country, due to nut
(Castanea sativa Miller) production.11 The nuts are tradition-
ally used for human and animal feed, by incorporation in
many dishes and desserts of Portuguese gastronomy.
Moreover, chestnuts seem to have beneficial properties for
human health.12–14 The leaves may be used for medicinal pur-
poses, such as colds, diarrhoea and to control blood chole-
sterol levels.15,16 Their flowers are reported by ancestral claims
as having health benefits as mucolytic, antispasmodic and
anti-dysenteric agents.17 The phytochemical profile of chestnut
tree flowers includes: flavonoids, such as catechin, myricetin
3-O-glucoside, quercetin 3-O-rutinoside, quercetin 3-O-gluco-
side, kaempferol 3-O-rutinoside and kaempferol 3-O-glucoside
and phenolic compounds, such as trigalloyl-HHDP-glucoside
and pentagalloyl glucoside.15 The in vitro antitumor activity of
decoctions and infusions of CF was evaluated by Carocho and
colleagues in four human tumour cell lines: MCF7 (breast
adenocarcinoma), HCT15 (colon carcinoma), HeLa (cervical
carcinoma) and HepG2 (hepatocellular carcinoma); higher
antitumoral activity against the colon and hepatocellular
cancer cell lines was observed.18 These authors concluded that
the anticancer properties may be related to the presence of two
polyphenols: trigalloyl-HHDP-glucoside and pentagalloyl-glu-
coside, found in the chestnut flowers.18
The present study aimed to evaluate the effect of CF in vivo,
using an animal model of chemically and hormonally
induced PCa. Furthermore, we also assessed the hepatic tox-
icity and antioxidant response to the administration of the CF
extract.
2. Materials and methods
2.1. Chestnut flower samples and decoction preparation
Castanea sativa Mill. Flowers (CFs), corresponding to upright
catkins during anthesis (flower fully opened and functional),
were collected in June 2017 in Bragança, (north-eastern
Portugal). The specimens were lyophilized (FreeZone 4.5,
Labconco, Kansas, USA), milled down to a fine powder, and
stored at room temperature, without humidity until the ana-
lysis. For the decoctions’ preparation, the lyophilized flowers
(1 g) were added to 200 mL of boiling distilled water, boiled
for 5 min, and then left to stand at room temperature for
5 minutes. After filtration through a Whatman filter paper, the
obtained decoctions were frozen and lyophilized. Based on the
phenolic compounds’ concentration and on the mean value of
the GI50 values obtained in the in vitro studies (300 µg mL
−1)
performed previously by Carocho et al.,18 the extract was admi-
nistrated at the quantity of 3 mg per day per animal in the
total drinking water amount per day. This amount (10× the
concentration of the GI50 value) was chosen to guarantee the
activity in vivo and to assure the phenolic compounds concen-
tration in the drinking water.
2.2. Phenolic compound profiles and stability of the aqueous
extracts
The phenolic compounds were determined in a Dionex
Ultimate 3000 UPLC (Thermo Scientific, San Jose, CA, USA)
connected to a diode-array detector (DAD, 280, 330 and
370 nm) and a mass spectrometer equipped with an ESI
source (Linear Ion Trap LTQ XL, Thermo Finnigan, San Jose,
CA, USA), following a procedure previously reported.19 The
identification was performed considering data reported in the
literature and the phenolic compounds previously identified
in chestnut flowers.11 For quantitative analysis, a calibration
curve for each available phenolic standard was constructed
based on the UV signal or, when no commercial standard was
available, a similar compound from the same phenolic group
was used as a standard and the results were expressed in µg
per mL of decoction. The stability of the drinking water was
evaluated during 5 consecutive days, at room temperature. In
this study, the aqueous extract was prepared at the feeding
concentration and analyzed daily through an LC-DAD-ESI/MS
system, to detect the degradation of any compounds.
2.3. Animals
Forty male Wistar Unilever rats (Rattus norvegicus) 4 weeks of
age were obtained from Charles River Laboratories (France).
The animals were maintained under controlled conditions of
temperature (23 ± 2 °C), humidity (50 ± 10%), air system fil-
tration (10–20 ventilations per hour) and light : dark cycles
(12 h : 12 h). They had ad libitum access to water and a stan-
dard laboratory diet (Mucedola 4RF21®, Milan, Italy). Cages
were cleaned and changed weekly, and the water was renewed
every three consecutive days. Animals were weighed weekly and
the ponderal homogeneity index [PH = 2Wi/(Wi + Wh)] and
ponderal gain [PG = W2 − W1/W2 × 100] were determined, with
Wi being the lowest animal weight, Wh the highest animal
weight, W1 the initial body weight and W2 the final body
weight. All procedures were performed according to the
European Directive 2010/63/EU on the protection of animals
used for scientific purposes and approved by the Portuguese
authorities (Direcção Geral Alimentação e Veterinária, Approval
no. 021326).
2.4. Experimental procedures
After one week of acclimatization, animals were randomly
assigned to four experimental groups as follows (Fig. 1): the
control group (n = 10), induced group (n = 15), control + CF
group (n = 5) and induced + CF group (n = 10). At 12 weeks of
age, the animals from the induced and induced + CF groups
received a subcutaneous injection of the anti-androgenic drug
flutamide (50 mg kg−1; TCI Chemicals, Portland, OR, USA) for
21 consecutive days. Twenty-four hours after the last flutamide
administration, testosterone propionate (TCI Chemicals,
Portland, OR, USA) was dissolved in corn oil and subcu-
taneously administered to the animals at a dose of 100 mg
kg−1. Forty-eight hours later, they were intraperitoneally
injected with the carcinogen agent MNU (Isopac®, Sigma
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Chemical Co., Madrid, Spain) at a dose of 30 mg kg−1. Two
weeks later, silastic tubes filled with crystalline testosterone
(Sigma Chemical Co., Madrid, Spain) were subcutaneously
implanted in the interscapular region of animals previously
anesthetized with ketamine (75 mg kg−1, Imalgene® 1000,
Merial S.A.S., Lyon, France) and xylazine (10 mg kg−1,
Rompun® 2%, Bayer Healthcare S.A., Kiel, Germany), remain-
ing until the end of the experimental protocol. Animals from
the control + CF and induced + CF groups were exposed to the
CF extract in drinking water, at a dose of 3 mg per animal per
day, since the beginning of the carcinogenic protocol and for
49 weeks. The animals’ food and water consumption was
recorded weekly at the same time and body weight was regis-
tered once a month. Animals were sacrificed at 61 weeks of life
through an intraperitoneal injection of ketamine (75 mg kg−1,
Imalgene® 1000, Merial S.A.S., Lyon, France) and xylazine
(10 mg kg−1, Rompun® 2%, Bayer Healthcare S.A., Kiel,
Germany), followed by exsanguination by cardiac puncture. A
complete necropsy was performed in all animals. All organs
were collected and weighed. The anterior prostate lobes and
seminal vesicle were individualized and weighed separately.
The ventral and dorsolateral prostate surrounding the prostatic
urethra were weighed as a block.
2.5. Serum biochemistry
The blood samples were allowed to clot and were centrifuged
at 3000 rpm for 15 minutes (4 °C). The serum was separated
and frozen at −80 °C until use. Serum concentrations of
albumin, total protein, glucose and alanine aminotransferase
(ALT) were determined in an autoanalyzer (Prestige 24i,
Cormay PZ).
2.6. Histological analysis
The prostate, liver and kidneys were fixed in 10% neutral
buffered formalin and processed for histological analysis
according to the routine technique. The following trimming
procedure was performed in all experimental groups: anterior
prostate, ventral prostate and seminal vesicle were bisected
midway and both sections were embedded in paraffin. The
dorsolateral prostate was transversely sectioned into three
slices and embedded in paraffin with the cut surface down.
The tissue sections were stained with hematoxylin and eosin
for histological analysis. The severity of non-proliferative and
inflammatory lesions was scored semi-quantitively in three
grades, as follows: (1) minimal – occurring in less than 10% of
prostate tissue; (2) mild – 10–50%; and (3) severe – more than
50%. All preneoplastic and neoplastic lesions were classified
according to Bosland et al.20
2.7. Oxidative stress parameters
2.7.1. Sample preparation. Liver samples were collected
from animals of different experimental groups for oxidative
stress analysis. A liver portion was weighed (±1 g) and added to
20% (w/v) ice-cold phosphate buffer. The samples were
mechanically homogenized and sonicated for 2 minutes. The
resulting homogenate was centrifuged in three different centri-
fugations cycles, at 4 °C: 1500g, 10 minutes (PS1-total mem-
brane fraction); 8000g, 10 minutes (mitochondrial fraction);
Fig. 1 (A) The experimental protocol and (B) the PCa induction protocol.
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and 14 000g, 10 minutes (PS2-mitochondrial fraction). The
supernatant resulting from the last centrifugation was immedi-
ately used for the assessment of the reduced glutathione
(GSH) and oxidised glutathione (GSSG) ratio, and to evaluate
the antioxidant enzymes’ activity. Lipid peroxidation was eval-
uated in both the total and mitochondrial membrane frac-
tions. The biuret method was used to determine the total
protein content from all pellets and supernatant collected.
2.7.2. Lipid peroxidation. Lipid peroxidation was evaluated
spectrophotometrically, at 532 nm, using the appearance of
malondialdehyde (MDA), according to Ottolenghi (1958) with
minor modifications.21 This method allows the determination
of the lipidic hydroperoxides from the amount of thio-
barbituric acid reactive substances (TBARS) formed. A volume
corresponding to 0.5 mg of protein was collected from the
total and mitochondrial lipidic fractions and added to 1 mL of
the thiobarbituric acid reagent. The mixture was homogenized,
heated for 15 minutes at 100 °C, and cooled down by ice
immersion. A centrifugation cycle was performed at 1600g for
10 minutes, at 4 °C, in order to collect the supernatant for the
assay. Results were expressed as μM (MDA), using the molar
coefficient extinction of 1.56 × 105 M−1 cm−1.
2.7.3. GSH/GSSG. The GSH and GSSG ratio was determined
by evaluating the GSH and GSSG levels. GSH and GSSG con-
centrations were assessed fluorometrically, at 339 nm (exci-
tation) and 426 nm (emission) using the fluorochrome ortho-
phthalaldehyde (OPT), as described by Hissin and Hilf
(1976).22 To determine the GSH levels, the supernatant col-
lected from all samples was incubated in a solution containing
potassium phosphate buffer (100 mM, EDTA 5 mM, pH 8.0)
and OPT (1 mg mL−1 ethanol), for 15 minutes at room temp-
erature. The samples’ supernatant was incubated for
30 minutes, at room temperature, with N-ethylmaleimide to
assess the GSSG concentration. A volume of NaOH (100 mM)
and OPT (1 mg mL−1 ethanol) was added to the mixture and
incubated in the darkness for 15 minutes. Concentrations of
GSH and GSSG were obtained using standard curves made
with known concentrations of GSH and GSSG, respectively.
Results were expressed as the ratio of GSH/GSSG.
2.7.4. Antioxidant enzymes. All antioxidant enzyme assays
were performed spectrophotometrically at 30 °C, except for cat-
alase (CAT) assessment. CAT activity was evaluated according
to Del Río (1977),23 using a Clark-type oxygen electrode. The
addition of a sample volume corresponding to 0.5 mg protein
to a mix containing potassium phosphate buffer (50 mM, pH
7.0) and hydrogen peroxide (8.82 M), started the enzymatic
reaction. CAT activity was expressed in mmol H2O2 consumed
per min Per mg protein. Superoxide dismutase (SOD) was
assayed at 560 nm, as described by Payá (1992),24 using the
xanthine–xanthine oxidase systems. The reaction mixture con-
tained potassium phosphate buffer (50 mM), EDTA (1 Mm) at
pH 7.4, hypoxanthine (10 mM), nitroblue tetrazolium chloride
(NBT, 10 mM) and a volume of the sample corresponding to
0.5 mg of protein. The kinetic reaction was started by adding
xanthine oxidase (0.0023 U mol−1). Results were expressed as
U min−1 mg−1 protein. One unit of SOD corresponds to the
amount of enzyme, inhibiting the reduction rate of NBT to for-
mazan by 50%. Glutathione reductase (GR) was assayed at
340 nm, as described by Carlberg and Mannervik.25 The reac-
tion system consisted of potassium phosphate buffer
(100 mM, EDTA 0.5 mM, pH 7.4), NADPH (10 mM) and 1.5 mg
of enzymatic extract. GSSG (100 mM) was added to the mixture
to start the kinetic reaction. Results were expressed as μmol
NADPH oxidized per min per mg protein. Glutathione-S-trans-
ferase (GST) was performed by the method described by
Hatton at 340 nm. The kinetic reaction was started by adding
GSH (100 mM) to the system reaction containing potassium
phosphate buffer (100 mM, pH 7.0) and 2,4-dinitrochloroben-
zene (CDNB, 100 mM). GST activity was expressed as mM of
CDNB conjugated per min per mg protein.
2.8. Statistical analysis
The data of oxidative stress was statistically analysed by using
ANOVA followed by Tukey’s Multiple Comparison Test
(GraphPad Prism software, version 7.0). The remaining con-
tinuous data were analysed with the Statistical Package for
Social Sciences (SPSS) version 25 (Chicago, IL, USA), by using
ANOVA followed by a Bonferroni test. Histological results were
analysed using a Chi-square test. The organs’ mean relative
weight was determined (weight of the organ/final body weight
of each animal). Data are presented as mean ± standard error
(S.E.) or mean ± standard deviation (S.D.). Data was considered
statistically significant for p values lower than 0.05.
3. Results
3.1. Phenolic composition
The phenolic profile of the CF decoctions extract is presented
in Table 1. Twenty-seven compounds were detected, from
which 14 were flavonoids and 13 were ellagitannins. These
compounds were previously described by Carocho and col-
leagues in two types of aqueous extracts (infusions and decoc-
tions), where trigalloyl-HHDP-glucoside, followed by pentagal-
loyl glucoside, were the most abundant compounds, as found
in the decoction extract of this study.15 Moreover, quercetin 3-
O-glucuronide was the most abundant flavonoid.15 The stabi-
lity of these extracts was studied during five consecutive days
and the concentration of phenolic compounds did not
decrease at day five (data not shown). Therefore, the drinking
water was maintained up to a maximum of three days, to avoid
compound degradation.
3.2. Body weight and mortality rate
The ponderal homogeneity index (PH), mortality rate, mean
initial and final animals’ body weight, and ponderal gain (PG)
may be observed in Table 2. The pH is an indicator of the
initial homogeneity of the experimental groups. Animals from
the control + CF group showed the highest PH variation (0.96)
and the control group showed the lowest variation (0.85).
Although the animals were acquired at the same age, their
body weight was different. During the experimental work, two
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animals died: one animal from the induced group and one
animal from the induced + CF group. Data from these animals
was excluded from the study. At the beginning of the experi-
mental work, the mean animals’ body weight was not statisti-
cally different among the groups. However, a statistically sig-
nificant difference was observed in the mean body weight
between the control and induced groups at the end of the
study (p < 0.05). The PG was higher in the control and control
+ CF groups, when compared with the induced and induced +
CF groups, respectively (p < 0.05). Table 3 shows the mean
values of food and water consumption at the beginning and at
the end of experimental work. Concerning the food consump-
tion, a significant difference (p < 0.05) was observed between
the induced and induced + CF groups in week one of the
study. The animals exposed to the CF extract showed the
highest water consumption at the beginning and the lowest
intake at the end of the study. Table 4 shows the relative organ
weight. The induced + CF group showed the highest mean rela-
tive prostate weight (0.0041 ± 0.0001), which is statistically
different from the control + CF group (p < 0.05). The liver
mean relative weight was higher in animals exposed to the CF
extract when compared with those not exposed. Statistically
Table 1 The identification and quantification (µg mL−1) of the phenolic compounds present in the Castanea sativa flower decoction extract via







ion [M − H]− (m/z) MS2 (m/z) (% of base peak) Tentative identificationa
Quantification
(µg mL−1)
1 4.96 276 783 481(100), 301(37) Pedunculagin isomer (bis-HHDP-glucose) 51.1 ± 0.3
2 5.79 268 783 481(100), 301(46) Pedunculagin isomer (bis-HHDP-glucose) 11.1 ± 0.6
3 7.06 272 633 463(18), 301(100) Galloyl-HHDP-glucose 30.4 ± 0.5
4 7.67 274 937 637(100), 467(3), 301(3) Trigalloyl-HHDP-glucose 28.4 ± 0.8
5 8.02 278 289 245(100), 203(66), 137(34) (+)-Catechin 11.7 ± 0.3
6 13.77 276 939 631(23), 469(69), 169(100) Pentagalloyl glucose 54.4 ± 0.7
7 14.92 276 935 633(100), 301(22) Galloyl-bis-HHDP-glucose 4.4 ± 0.4
8 15.25 274 933 915(20), 633(100), 451(22), 301(11) Castalagin/vescalagin 7.3 ± 0.5
9 15.46 278 907 767(55), 607(100), 467(55), 169(8) Galloyl-HHDP derivative 3.7 ± 0.2
10 16.13 274 937 767(22), 637(36), 467(100), 301(15) Trigalloyl-HHDP-glucoside 259 ± 1
11 16.65 358 493 317(100) Myricetin O-glucuronide 11.0 ± 0.2
12 17.07 350 479 317(100) Myricetin 3-O-glucoside 6.4 ± 0.1
13 17.30 274 937 767(5), 637(22), 467(100), 301(5) Trigalloyl-HHDP-glucoside 12.91 ± 0.05
14 19.89 356 609 301(100) Quercetin 3-O-rutinoside 15.3 ± 0.1
15 20.64 356 477 301(100) Quercetin 3-O-glucuronide 34 ± 1
16 20.86 356 463 301(100) Quercetin 3-O-glucoside 17.5 ± 0.1
17 21.30 356 463 301(100) Quercetin O-hexoside 21.5 ± 0.7
18 23.54 350 593 285(100) Kaempferol 3-O-rutinoside 2.0 ± 0.1
19 24.05 354 433 301(100) Quercetin O-pentoside 4.2 ± 0.2
20 24.46 268 907 767(7), 607(33), 467(100), 169(8) Galloyl-HHDP derivative 40.5 ± 0.9
21 25.11 348 447 285(100) Kaempferol 3-O-glucoside 5.14 ± 0.04
22 26.00 354 477 315(100) Isorhamnetin O-hexoside 3.2 ± 0.4
23 26.25 354 491 315(100) Isorhamnetin O-glucuronide 3.4 ± 0.3
24 27.71 274 907 767(7), 607(47), 467(100), 169(11) Galloyl-HHDP derivative 19.7 ± 0.6
25 29.87 250/368 343 328(93), 313(100), 298(43) Tri-O-methylellagic acid 1.0 ± 0.1
26 32.38 358 609 463(55), 301(100) Quercetin O-rhamnosyl hexoside 2.20 ± 0.01
27 33.13 356 519 477(44), 315(100) Isorhamnetin O-acetylhexoside 1.08 ± 0.01
Total flavonoids 139.0 ± 0.5
Total ellagitannins 524.2 ± 0.4
Total phenolic compounds 663.1 ± 0.9
Calibration curves: catechin (y = 132.76x − 59.658; R2 = 1); gallic acid (y = 556.94x − 738.37; R2 = 0.999); isorhamnetin-3-O-glucoside (y = 262.31x
− 9.8958; R2 = 1); kaempferol-3-O-glucoside (y = 190.75x − 36.158; R2 = 1); kaempferol-3-O-rutinoside (y = 175.02x − 43.877; R2 = 0.999); myricetin
(y = 778x − 1454.3; R2 = 0.999); quercetin-3-O-glucoside (y = 316.48x − 2.9142; R2 = 1.000); and quercetin-3-O-rutinoside (y = 222.79x − 243.11; R2
= 0.999). a Carocho et al. (2014).15
Table 2 Number of animals, ponderal homogeneity index (PH), mortality rate, initial and final animal body weights (g) [mean ± standard error (SE)],











Control 10 10 0.85 0 144 ± 4.2 546 ± 3.5a 73.5 ± 0.5a
Induced 15 14 0.86 7 152 ± 2.8 495 ± 9.5 69.3 ± 0.7
Control + CF 5 5 0.96 0 157 ± 4.4 561 ± 8.3 72.0 ± 0.6b
Induced + CF 10 9 0.94 10 172 ± 1.3 534 ± 7.1 67.8 ± 0.5
a p < 0.05 versus the induced group. b p < 0.05 versus the induced + CF group.
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significant differences were observed between the control
groups (control and control + CF, p < 0.05) and between the
induced groups (induced and induced + CF, p < 0.05).
3.3. Blood sample analysis
The animals’ biochemical profile may be consulted in Table 5.
No significant differences were observed in the serum levels of
albumin and ALT among the groups. Although the differences
were not statistically significant, glucose serum levels were
lower in animals exposed to the CF extract than in those not
exposed, either in the control or induced groups.
3.4. Histopathology
The prostate lesions identified in each experimental group are
listed in Tables 6 and 7 and some lesions may be observed in
Fig. 2. Prostate lesions were classified as dysplasia, prostatic
intraepithelial neoplasia (PIN), and microinvasive carcinoma.
Animals from the control group exposed to the CF extract
presented an increased frequency in the dorsolateral prostate
of preneoplastic, dysplastic and PIN lesions. In the induced
groups, CF did not significantly change the frequency of dys-
plasia, PIN, and neoplastic lesions (microinvasive carcinoma).
Regarding the ventral and anterior prostate lobes, histological
lesions were only observed in animals from the induced + CF
group; in these lobes CF exposure slightly increased the lesion
frequency, although the differences were not statistically sig-
nificant. When combining the data from all the prostate lobes,
CF increased dysplasia in the controls and tended to increase
PIN (p = 0.08), but did not significantly affect induction of dys-
plasia, PIN and microinvasive carcinoma in the induced
groups (Table 7).
Data about inflammation on the dorsolateral prostate lobe,
the most affected lobe in this protocol, may be observed in
Table 8. Inflammation in the dorsolateral prostate lobe was
observed in all experimental groups. The most extensive and
severe inflammation foci were observed in the induced group,
with 50.0% (7/14) of the rats exhibiting severe inflammation of
prostate tissue, whereas all animals of the induced + CF group
showed less extensive inflammation. Regarding the liver his-
tology, only three animals (33.3%) from the induced + CF
group developed panlobular, but moderate, hydropic changes,
while all the other animals showed occasional, small and
slight hydropic change foci. Occasional fatty change foci were
observed in rats from the induced group and in two obese
animals from the control group. No severe degenerative, necro-
tic or inflammatory changes were observed in the assay. In
some groups (induced and induced + CF) we also observed
occasional small foci of coagulative to liquefactive necrosis, or
isolated necrotic cells. Mitosis, anisokaryosis or multinu-
cleated hepatocytes were rarely observed.
Regarding the kidneys, no severe nor diffuse necrotic and/
or inflammatory foci were observed in all groups in the study
Table 4 Mean relative organ weights (g) in each experimental group (mean ± SE)
Control (n = 10) Induced (n = 14) Control + CF (n = 5) Induced + CF (n = 9)
Prostate 0.0021 ± 0.0001a,b 0.0040 ± 0.0002 0.0028 ± 0.0001c 0.0041 ± 0.0001
Liver 0.0224 ± 0.0014b 0.0256 ± 0.0006c 0.0273 ± 0.0006c 0.0325 ± 0.0009
Left kidney 0.0029 ± 0.0001a 0.0037 ± 0.0011 0.0028 ± 0.0001c 0.0035 ± 0.0001
Right kidney 0.0030 ± 0.0002a 0.0039 ± 0.0001 0.0029 ± 0.0000c 0.0036 ± 0.0000
a p < 0.05 versus the induced group. b p < 0.05 versus the control + CF group. c p < 0.05 versus the induced + CF group.
Table 3 Mean food and water consumption (g) (mean ± SE) at the beginning and at the end of the experimental protocol
Control (n = 10) Induced (n = 14) Control + CF (n = 5) Induced + CF (n = 9)
Food consumption (g) Initial 14.9 ± 0.1 13.7 ± 1.2a 18.9 17.2 ± 0.1
Final 19.6 ± 0.6b 20.9 ± 0.1 20.2 20.9 ± 0.1
Water consumption (g) Initial 19.6 ± 0.01b,c 18.41 ± 0.1a 23.4b 21.9 ± 0.2
Final 24.1 ± 0.1b,c 25.5 ± 0.5a 11.6a 15.4 ± 0.0
a p < 0.05 versus the induced + CF group. b p < 0.05 versus the induced group. c p < 0.05 versus the control + CF group.
Table 5 Biochemical profiles of all the experimental groups (mean ± SE)
Control (n = 10) Induced (n = 14) Control + CF (n = 5) Induced + CF (n = 9)
Albumin (g L−1) 42.45 ± 2.16 40.56 ± 1.07 38.24 ± 2.40 37.18 ± 1.66
Total protein (g L−1) 63.14 ± 2.60a 57.01 ± 0.86 54.51 ± 4.09 50.51 ± 3.79
Glucose (mg dL−1) 265.39 ± 24.58 254.16 ± 13.01 236.14 ± 20.56 225.92 ± 25.37
ALT (U L−1) 38.93 ± 4.65 39.15 ± 2.91 34.40 ± 8.48 24.48 ± 2.02
a p < 0.05 versus the induced group.
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(Table 9). All animals from the induced + CF group developed
small multifocal non-purulent interstitial nephritis foci,
whereas focal nephritis was just observed in 42.9% (6/14) of
animals from the induced group. No animals exposed to the
CF extract developed chronic multifocal lesions, but these
lesions were observed in 21.4% (3/14) of the non-treated
animals (Table 9).
3.5. Oxidative stress evaluation
Nonspecific lipid peroxidation levels were evaluated by the
formed TBARS products in both lipid fractions – total and
mitochondrial (Fig. 3). The induced group and the groups
exposed to the CF extract (control and induced) showed
similar levels of formed TBARS products in the total and mito-
chondrial fraction. Induced animals showed a decrease of 28%
and 24% of lipid peroxidation levels in total and mitochon-
drial fractions, respectively, when compared to control
animals. However, this reduction did not reach statistical sig-
nificance (p > 0.05). The administration of the CF extract to
the control group led to a statistically significant decrease of
the formed TBARS products by 68% and 57% of the total and
mitochondrial fraction, respectively (p = 0.004). However, the
administration of the CF extract in the induced animals
caused a 25% increase in lipid peroxidation in both lipid frac-
tions, when compared with the control + CF group (p > 0.05).
Prostate cancer induction and administration of the CF extract
to both control and induced rats did not promote any statisti-
cally significant alteration in GSH/GSSG (p > 0.05) (Fig. 4). The
activity of antioxidant enzymes showed a different response to
cancer induction and CF extract treatment. SOD and GR
activity did not show statistically significative alterations in any
experimental group. An increase of 32% and 17% was observed
in CAT and GST activity, respectively (p < 0.007). The adminis-
tration of CF to control animals did not promote any alteration
in the activity of antioxidant enzymes when compared to the
control group. In induced animals, the administration of CF
decreased the activity of CAT and GST by 36% and 20%,
respectively (p < 0.0007).The administration of the CF extract
to the induced group led to the activities of CAT and GST
being close to the values observed in the control group. Thus,
CF extract administration seems to induce a normalization of
the enzymatic antioxidant system (Fig. 5).
4. Discussion
Rats are commonly used as models in experimental PCa
research.3,26 Although rat and human prostates have anatom-
ical differences, the mechanisms underlying prostate tumori-
genesis are similar.4 While the human prostate is a compact
and a lobular structure, the rat prostate is composed of four
lobes – the ventral, dorsal, lateral and anterior lobe (or coagu-
lating gland) – with different histological characteristics.27,28
The dorsal and lateral lobes are commonly referred to as the
dorsolateral lobe due to the difficulty of anatomical division
and similar histological features.29 These lobes are homolo-
gous to the peripheral zone of the human prostate,30 where
most carcinomas arise.31 The induction protocol used in the
present work was based on the works previously published by
Bosland,26,32 where a multistep protocol was employed –
animals were administered with an antiandrogen, testosterone
propionate, a specific carcinogen and chronically exposed to
testosterone using subcutaneous implants.26,32,33 Prostate
Table 7 Number of animals (%) with dysplasia, PIN, and microinvasive










Absent 6 (60%) 2 (14.3%) 0 (0.0%) 0 (0.0%)
Present 4 (40%)a,b 12 (85.7%) 5 (100.0%) 9 (100.0%)
PIN
Absent 9 (90.0%) 6 (42.9%) 2 (40.0%) 2 (22.2%)
Present 1 (10.0%)a 8 (57.1%) 3 (60.0%) 7 (77.8%)
Microinvasive carcinoma
Absent 10 (100.0%) 5 (35.7%) 4 (80.0%) 1 (11.1%)
Present 0 (0.0%)a 9 (64.3%) 1 (20.0%)c 8 (88.9%)
a p < 0.05 versus induced group. b p < 0.05 versus control + CF group. c p
< 0.05 versus induced + CF group.
Table 6 Number of animals (%) with histological lesions in prostate











Absent 6 (60.0%) 2 (14.3%) 0 (0%) 1 (11.1%)
Present 4 (40.0%)a,b 12 (85.7%) 5 (100.0%) 8 (88.9%)
PIN
Absent 9 (90.0%) 5 (35.7%) 2 (40%) 3 (33.3%)
Present 1 (10.0%)a,b 9 (64.3%) 3 (60.0%) 6 (66.7%)
Microinvasive carcinoma
Absent 10 (100.0%) 5 (35.7%) 4 (80.0%) 2 (22.2%)
Present 0 (0.0%)a 9 (64.3%) 1 (20.0%) 7 (77.8%)
Ventral prostate
Dysplasia
Absent 10 (100.0%) 14 (100.0%) 5 (100.0%) 7 (77.8%)
Present 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (22.2%)
PIN
Absent 10 (100.0%) 14 (100.0%) 5 (100.0%) 8 (88.9%)
Present 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (11.1%)
Microinvasive carcinoma
Absent 10 (100.0%) 10 (100.0%) 10 (100.0%) 10 (100.0%)
Present 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Anterior prostate
Dysplasia
Absent 10 (100.0%) 14 (100%) 5 (100.0%) 6 (66.7%)
Present 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (33.3%)
PIN
Absent 10 (100.0%) 14 (100%) 5 (100.0%) 7 (77.8%)
Present 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (22.2%)
Microinvasive carcinoma
Absent 10 (100.0%) 14 (100%) 5 (100.0) 7 (77.8%)
Present 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (22.2%)
a p < 0.05 versus the induced group. b p < 0.05 versus the control group
+ CF; PIN – intraepithelial neoplasia.
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tumours are mainly induced in the dorsolateral and anterior
prostate lobes.26,32,33
Natural compounds are widely used against several dis-
eases, including cancer.6,34,35 The chestnut tree, a typical
Mediterranean tree, has a variety of applications.15 The flowers
have been used for medical purposes due to their antioxidant
properties and antimicrobial and antitumoral effects.11,18
In the present work, the effect of the CF extract was evalu-
ated in a rat model of chemically and hormonally induced
PCa. The mean final body weight of animals exposed to CF
Fig. 2 Histopathological lesions observed in the dorsolateral prostate, DLP, (A–C) and in the anterior prostate, AP, (D–F) via hematoxylin and eosin
staining: (A) dysplasia in the DLP, (B) intraepithelial neoplasia in situ (PIN) in the DLP, (C) microinvasive carcinoma in the DLP (the arrow shows the
invasion front of the tumor, with carcinoma cells forming small tubules and nests), (D) hyperplasia in the AP, (E) PIN in the AP, and (F) microinvasive
carcinoma in the AP (the arrow shows invasive tumor cell nests).












<10% 2 (20.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
10–50% 8 (80.0%) 7 (50.0%)a 5 (100.0%) 9 (100.0%)
>50% 0 (0.0%)b 7 (50.0%)a 0 (0.0%) 0 (0.0%)
a p < 0.05 versus the induced + CF group. b p < 0.05 versus induced
group.
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flower extract was not different from the respective control
groups. The animals’ body weight increased throughout the
study in all experimental groups. The animals from control
and induced groups exposed to the CF extract showed a lower
water intake when compared to the unexposed groups, which
may be related to the water taste due to the presence of CF
extract. One of the requisite of a rat PCa model is the develop-
ment of adenocarcinomas histologically similar to those devel-
oped by men in the dorsal and lateral prostate lobes, which
are human homologues.26 In this study, preneoplastic and
neoplastic prostate lesions were found mainly in the dorsolat-
eral lobe. These data are in accordance with previous studies
employing a similar experimental protocol, which reported an
incidence of carcinomas in the dorsolateral prostate of
approximately 60–80%, within 50–60 weeks after MNU
administration.36–42 In our study, CF was not associated with
an increased frequency of pre-neoplastic and neoplastic
lesions in the dorsolateral prostate in the induced groups but
Table 9 Number of animals (%) with liver and kidney histological






CF (n = 5)
Induced +
CF (n = 9)
Liver
Cell changes
Absent 8 (80.0%)a 6 (42.9%) 3 (60.0%) 0 (0.0%)
Focal vacuolar
change
2 (20.0%) 5 (35.7%)b 0 (0.0%) 0 (0.0%)
Slight hydropic
change




0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (33.3%)
Inflammatory infiltrate
Absent 3 (30.0%)c 3 (21.4%) 5 (100%) 4 (44.4%)
Focal 7 (70.0%)c 11 (78.6%) 0 (0.0%) 5 (55.6%)
Extensive 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Necrosis
Absent 10 (100.0%) 12 (85.7%) 5 (100.0%) 8 (88.9%)
Focal 0 (0.0%) 2 (14.28%) 0 (0.0%) 1 (11.1%)
Kidney
Non-purulent interstitial nephritis
Absent 3 (30.0%) 4 (28.6%) 1 (20.0%) 0 (0.0%)
Focal 5 (50.0%) 4 (28.6%) 4 (80.0%)b 0 (0.0%)
Multifocal 2 (20.0%) 6 (42.9%) 0 (0.0%)b 9 (100.0%)
Chronic nephritis
Absent 8 (80.0%)a 5 (35.7%) 1 (20.0%) 5 (55.6%)
Focal 1 (10.0%)c 6 (42.9%) 4 (80.0%) 4 (44.4%)
Multifocal 1 (10.0%) 3 (21.4%)b 0 (0.0%) 0 (0.0%)
Proteinuria
Absent 5 (50.0%) 5 (35.7%) 4 (89.0%)b 0 (0.0%)
Discrete 5 (50.0%) 9 (64.3%) 1 (20.0%)b 9 (100.0%)
Intense 0 (0.0%) 0 (0.0%) 0 (0.0%) 0(0.0%)
Cytomegalocytosis
No 10 (100.0%) 14 (100.0%) 5 (100.0%) 7 (77.8%)
Yes 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (22.2%)
a p < 0.05 versus the induced group. b p < 0.05 versus the induced + CF
group. c p < 0.05 versus control + CF group.
Fig. 3 Evaluation of hepatic lipid peroxidation: (A) MDA concentrations in the total lipidic fraction isolated from livers and (B) the MDA concen-
trations in the mitochondrial lipidic fraction isolated from livers. Results were obtained from the four experimental groups: control, induced, control
+ CF, and induced + CF groups. Columns with different letters were statistically different (p < 0.05). Data are presented as mean ± S.D. (n = 7) from
two replicates.
Fig. 4 Evaluation of the hepatic GSH/GSSG ratio. Results were obtained
from the four experimental groups: control, induced, control + CF, and
induced + CF groups. Columns with different letters were statistically
different (p < 0.05). Data are presented as mean ± S.D. (n = 7) from two
replicates.
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was associated with a slight increase of the frequency of
lesions on the control + CF compared to the control group.
Considering that these animals were not exposed to hormonal
treatment or carcinogen administration, and accounting the
animals’ age at sacrifice (61 weeks of age), they may be con-
sidered old; previous studies showed that aged Wistar rats are
susceptible to spontaneous lesions that mimic human prostate
alterations.43 Correlating the laboratory rat and human ages,44
we estimate that our rats correspond to a man over 40 years
old. At this age, the human prostate is more likely to develop
prostate disorders, such as benign prostate hyperplasia.45 It
also is important to highlight that functional hyperplasia is
commonly associated with prostate aging and may occur in all
animal species. Regarding ventral and anterior prostate CF
exposure, in induced animals there was a slight increase in
lesions frequency, but there were no significant differences.
All groups showed inflammation in the dorsolateral pros-
tate, which is in accordance with previous published studies.46
In the prostate, the CF extract appears to decrease the severity
of inflammation, as exposed CF animals showed fewer inflam-
mation areas.
The highest mean relative liver weight was observed in
induced animals treated with the CF extract, but these differ-
ences were not supported by biochemical parameters. For
example, the circulating levels of ALT, a marker of liver
damage47,48 was not different among the groups.
Macroscopically, most livers from the CF exposed animals had
increased in size and were paler than normal. These gross
changes in liver colour, size and weight can be associated with
hydropic changes observed microscopically, although it was
always focal, slight to mild. In fact, just three induced animals
+ CF developed panlobular and mild hydropic changes, and
no severe degenerative, necrotizing or inflammatory lesions
were observed in this study. The hydropic changes observed in
liver are usually associated with Na+/K+ pump disfunction
rather than with lipid cytoplasmic overload.
Circulating androgens play a role in prostate growth, which
will be strongly influenced by liver function, as most circulat-
ing androgen dihydrotestosterone originates in the liver. For
this reason, liver disease has been suggested to influence the
incidence of PCa. Nevertheless, the effect of liver function on
prostate lesions and PCa outcomes has not yet been
elucidated.49,50
Our results showed that PCa induction had an impact on
the hepatic antioxidant system, stimulating some of the anti-
oxidant enzymes analyzed. Systemic and prostate dysregulation
of redox balance has already been documented in PCa,
although the results are not similar.51–53 Nevertheless, in this
model, we may consider the toxic effect of chronic testosterone
exposure on liver tissue, as testosterone was released through
implants until the animals’ euthanasia. Therefore, the direct
impact on biomarkers cannot be excluded from the two
exposed groups. The CF extract induced a reduction in lipid
peroxidation in all groups (control and induced), both in
Fig. 5 Evaluation of hepatic antioxidant enzymes: (A) catalase activity; (B) superoxide dismutase activity; (C) glutathione reductase activity; and (D)
glutathione-S-transferase activity. Results were obtained from the four experimental groups: control, induced, control + CF, and induced + CF
groups. Columns with different letters were statistically different (p < 0.05). Data are presented as mean ± S.D. (n = 7) from two replicates.
Paper Food & Function





















































plasma and in the mitochondrial membranes, although not a
statistically significant difference. However, it is clear that
under the conditions tested, CF has a beneficial and protective
effect at the lipid membrane level, which probably results from
the action of some compounds that, due to their physical pro-
perties, tend to accumulate on the lipid membranes and exert
a protective effect. Effects of testosterone on reactive oxygen
species (ROS) generation and oxidant status are a controversial
subject. Depending on the experimental conditions, we may
observe an increase or a decrease in lipid peroxidation
measured by MDA production.54–58 The results regarding anti-
oxidant activities (SOD) are also variable, depending not only
on the experimental model, but also on the testosterone con-
centration administered.59,60 Regarding the activation of GST
(phase II enzyme), the effect observed in the liver has already
been described by the action of flutamide and
testosterone.61,62 Although few reports have addressed the anti-
oxidant potential of CF,18 a small number of studies have
focused on the antioxidant response induced by the consump-
tion of CF extracts. The presence of phenolic compounds and
some organic acids in the CF extract justify, among other ben-
eficial activities, the observed antioxidant activity, as they are
capable of free radical scavenging.15 However, most studies
used an in vitro approach resulting in a lack of knowledge
regarding the antioxidant response induced by CF consump-
tion.63 The enteral administration of the CF extract leads to a
systemic effect. Given the role of the liver in the metabolism of
substances that enter the gastrointestinal tract, it is expected
that the CF extract leads to changes in hepatic function. In our
results, the administration of CF in PCa-induced animals sig-
nificantly changed CAT, which came close to the control
group, suggesting a beneficial effect on oxidative stress
induced cancer. The decreased activity of antioxidant enzymes,
as well as lipid peroxidation levels observed with adminis-
tration of the CF extract may be interpreted as a response to
reduced ROS levels.
5. Conclusions
The most interesting finding from this study was the reduction
of inflammation on the dorsolateral prostate lobe. The CF
extract did not cause significant hepatic and renal toxicity, as
observed microscopically and via biochemical tests. Regarding
the effects of CFs on dorsolateral prostate tumorigenesis, no
significant differences were achieved between the induced and
induced + CF groups. Apparently, the CF extract has no signifi-
cant effect on MNU-initiated dorsal prostate cells. As inflam-
mation may act as a promotor (inflammation mediators, as
ROS, can also be initiators), the anti-inflammatory effects
may also have a protective influence against prostate
tumorigenesis.
The results from the different experimental groups corrobo-
rate the existence of physiological alterations in the livers of
animals with PCa, and they also showed that the use of CFs in
this group (PCa) induced changes in some enzymes of the
antioxidant system (CAT and GST). Considering the animal
model used, with animals subjected to prolonged testosterone
exposure, it is plausible that the results relating to oxidative
stress mainly reflect the effects of testosterone. New studies
are warranted to elucidate the real role of antioxidant
enzymes, oxidative stress, and the action of testosterone, not
only in the prostate but also in other organs. Also, new studies
on CFs using different doses should be performed to clarify if
CFs are in fact toxic in rat and/or human livers.
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